Benjamin Albert - 29 Apr 2026 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Reporting relationship: CEO, Director
Issuer ticker: HCAT
Reported as of: 29 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 May 2026, 16:33:02 UTC
Prior SEC filing: 13 Mar 2026
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Benjamin Landry, as Attorney-in-Fact

Key filing fact

Benjamin Albert filed Form 4 for Health Catalyst, Inc. (HCAT) on 01 May 2026.

Key facts

This page summarizes Benjamin Albert's Form 4 filing for Health Catalyst, Inc. (HCAT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 May 2026, 16:33.

Change

Previous filing in this sequence was filed on 13 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002086403 Primary reporting owner

Albert Benjamin

Relationship: CEO, Director
Address: 10897 S. RIVER FRONT PARKWAY, SUITE 300, SOUTH JORDAN
Signature: /s/ Benjamin Landry, as Attorney-in-Fact
Signature date: 01 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HCAT transaction

Common Stock

Award

Transaction value
Shares: +1,124
Change %: +0.08%
Price: $0.000000^*
Shares after: 1,459,102
Date: 29 Apr 2026
Ownership: Direct
Footnotes: F1

HCAT transaction

Common Stock

Tax liability

Transaction value
Shares: -310
Change %: -0.02%
Price: $1.34^*
Shares after: 1,458,792
Date: 01 May 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of 1,124 performance-based restricted units of the Issuer ("PRSUs") pursuant to the Issuer's 2019 Stock Option and Incentive Plan, based upon the Issuer's satisfaction of certain performance criteria for the fiscal year ended December 31, 2025, approved by the Issuer's board of directors on April 29, 2026. Each PRSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.